Spotlight on Internal Medicine

Credits: 0.50 CME
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD
Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Vindico

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

1.25 CME
Vindico
Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Start

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Systemic Lupus Erythematosus Management in a New Decade: Treat to Target, But Don’t Stop There

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 8, 2020
Expires: December 7, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with systemic lupus erythematosus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the immunopathology underlying systemic lupus erythematosus (SLE) and the implications for disease manifestations, burden, and treatment.
  • Assess patients with SLE for visceral organ involvement as well as steroid toxicity and manage accordingly.
  • Assess patients being treated for SLE for disease activity to ensure treatment to desired clinical target and symptom control.
  • Select treatment for children or adults with SLE based on the latest clinical evidence and guidelines.
  • Review the importance of effective communication, counseling, and shared decision-making strategies to improve adherence and satisfaction with care for patients with SLE.

Activity Description

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects both children and adults, with women of childbearing age being at greatest risk. Individuals diagnosed with SLE can have widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and the brain. Ongoing education is essential for providing evidence-based care for this complex disease. In this educational program featuring clinical case examples, experts will provide an overview of SLE immunopathology and offer guidance on assessment of disease activity, visceral organ involvement, and steroid toxicity. Faculty will review optimal management approaches per treatment guidelines, present recent clinical data, and highlight therapeutic advancements. Strategies for utilizing effective communication and shared decision-making to improve therapy adherence and patient satisfaction will be discussed.

Agenda

Introduction: Lupus—A Historical Perspective
Leonard H. Calabrese, DO

Immunopathogenesis of SLE: Implications for Disease Manifestations and Treatment
Daniel J. Wallace, MD, FACP, MACR

Advances in the Treatment of SLE
Richard A. Furie, MD
 
Clinical Cases
Moderated by Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB

Faculty

Richard A. Furie, MD
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology
Northwell Health
Great Neck, NY

Disclosures:
Consulting Fee: AstraZeneca, Aurinia, Genentech, GlaxoSmithKline

Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
Los Angeles, CA

Disclosures:
Consulting Fee: Aurinia, EMD Serono, GlaxoSmithKline, Lilly, Pfizer

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 8, 2020 to December 7, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
AcademicCME
Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Start

Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, physician assistants and other healthcare providers who care for patients with IBD.

Learning Objectives

  1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to reduce inflammation in patients with IBD
  2. Analyze ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with IBD
  3. Develop treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes

Activity Description

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how S1P receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and efficacy of novel S1P therapeutics to treat patients with IBD will be reviewed and analyzed. The faculty will also delve into treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes. Upon completion of this educational program, clinicians will gain better insight into how to better manage their patients with inflammatory bowel disease by utilizing S1P therapeutics.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with inflammatory bowel disease.

Agenda

  1. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for IBD
  2. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Crohn’s Disease and Ulcerative Colitis Disease
  3. Treatment Strategies for the Application of S1P Therapeutics to Optimize IBD Patient Outcomes

Faculty

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Conflict of Interest Policy/Disclosure Statement

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

William J. Sandborn, MD (Course Chair)

Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb Company; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc.; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics; Surrozen; Takeda Pharmaceutical Company; Theravance Biopharma; Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma

Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc.

Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.

Miguel Regueiro, MD

Consultant/Advisor: Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB

Grant/Research Support:AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company

David T. Rubin, MD

Consultant/Advisor: AbbVie Inc.; AbGenomics International, Inc.; Allergan; Biomica; Boehringer Ingelheim; Bristol Meyers Squibb Company; CDx Diagnostics; Check-Cap; Dizal Pharma; Eli Lilly and Company; Galen Limited; Genentech USA, Inc.; Gilead Sciences, Inc.; Ichnos Sciences S.A.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated.
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, physician assistants and other healthcare providers who care for patients with IBD.

Learning Objectives

  1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to reduce inflammation in patients with IBD
  2. Analyze ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with IBD
  3. Develop treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes

Activity Description

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how S1P receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and efficacy of novel S1P therapeutics to treat patients with IBD will be reviewed and analyzed. The faculty will also delve into treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes. Upon completion of this educational program, clinicians will gain better insight into how to better manage their patients with inflammatory bowel disease by utilizing S1P therapeutics.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with inflammatory bowel disease.

Agenda

  1. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for IBD
  2. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Crohn’s Disease and Ulcerative Colitis Disease
  3. Treatment Strategies for the Application of S1P Therapeutics to Optimize IBD Patient Outcomes

Faculty

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA

Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Conflict of Interest Policy/Disclosure Statement

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

William J. Sandborn, MD (Course Chair)

Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb Company; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc.; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics; Surrozen; Takeda Pharmaceutical Company; Theravance Biopharma; Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma

Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc.

Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.

Miguel Regueiro, MD

Consultant/Advisor: Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB

Grant/Research Support:AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company

David T. Rubin, MD

Consultant/Advisor: AbbVie Inc.; AbGenomics International, Inc.; Allergan; Biomica; Boehringer Ingelheim; Bristol Meyers Squibb Company; CDx Diagnostics; Check-Cap; Dizal Pharma; Eli Lilly and Company; Galen Limited; Genentech USA, Inc.; Gilead Sciences, Inc.; Ichnos Sciences S.A.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated.
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

1.25 CME
Vindico
Influenza in the Hospital: Perils and Pearls
0.75 CME
Vindico
Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Start

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with non-tuberculous mycobacteria (NTM).

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Employ appropriate clinical, imaging, and microbiologic criteria necessary for the diagnosis of NTM.
  • Utilize available evidence-based guidelines to effectively manage NTM pulmonary disease.
  • Incorporate the latest clinical data in the selection of therapy for refractory NTM pulmonary disease.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence.

In this expert panel video, faculty discuss three challenging cases of NTM lung disease. Experts provide guidance on utilization of appropriate diagnostic criteria and discuss evidence-based approaches to manage NTM pulmonary disease. Through case examples, they also review strategies for incorporating the latest clinical data in the selection of therapy for both newly diagnosed and refractory NTM disease.

Activity Chair

Anne E. O'Donnell, MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC

Disclosure:
Consulting Fee: Electromed, Insmed, Merck, Xellia
Contracted Research (Paid to Institution): Insmed

Faculty

David E. Griffith, MD, FACP, FCCP
Overseas Fellow Royal Society of Medicine
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Services Fees: Insmed
Contracted Research: Insmed

Angela DiMango, MD
Associate Professor of Clinical Medicine
Columbia University
Vagelos College of Physicians and Surgeons
New York, New York

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with non-tuberculous mycobacteria (NTM).

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Employ appropriate clinical, imaging, and microbiologic criteria necessary for the diagnosis of NTM.
  • Utilize available evidence-based guidelines to effectively manage NTM pulmonary disease.
  • Incorporate the latest clinical data in the selection of therapy for refractory NTM pulmonary disease.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence.

In this expert panel video, faculty discuss three challenging cases of NTM lung disease. Experts provide guidance on utilization of appropriate diagnostic criteria and discuss evidence-based approaches to manage NTM pulmonary disease. Through case examples, they also review strategies for incorporating the latest clinical data in the selection of therapy for both newly diagnosed and refractory NTM disease.

Activity Chair

Anne E. O'Donnell, MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC

Disclosure:
Consulting Fee: Electromed, Insmed, Merck, Xellia
Contracted Research (Paid to Institution): Insmed

Faculty

David E. Griffith, MD, FACP, FCCP
Overseas Fellow Royal Society of Medicine
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Services Fees: Insmed
Contracted Research: Insmed

Angela DiMango, MD
Associate Professor of Clinical Medicine
Columbia University
Vagelos College of Physicians and Surgeons
New York, New York

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Global Education Group
Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Fire Fight: Smothering the Flame of Type 2 Inflammation ̶ Advances in Understanding and Managing Type 2 Inflammatory Diseases

Start

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Fire Fight: Smothering the Flame of Type 2 Inflammation—Advances in Understanding and Managing Type 2 Inflammatory Diseases

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC Point(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of the type 2 inflammatory cascade in the underlying pathophysiology of atopic diseases
  • Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss type 2 Inflammation as an underlying cause of asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, with implications for therapeutic choices in patient care.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD, FAAD, is a clinical assistant professor of dermatology & pediatrics at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Lio received his medical degree from Harvard Medical School in Boston, MA, completed his internship in pediatrics at Boston Children’s Hospital and his residency in dermatology at Harvard University/Massachusetts General Hospital, where he served as the chief resident in dermatology. While at Harvard, he received formal training in acupuncture. Dr Lio is board certified in dermatology.

Dr Lio’s interests are in atopic dermatitis and connective tissue diseases, such as lupus and dermatomyositis. As a medical acupuncturist, his interests are in alternative medical approaches to dermatologic diseases.

Dr Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He currently serves as a board member and scientific advisory committee member for the National Eczema Association; a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group; and is a founding faculty member of the Integrative Dermatology Certificate Program. Dr Lio has over 150 publications and 3 textbooks.

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Joseph K. Han, MD, is a professor in the Department of Otolaryngology & Head and Neck Surgery at Eastern Virginia Medical School and is the chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery. He is also the chief for the Division of Allergy. Dr Han received his medical degree from the Medical College of Pennsylvania and completed an otolaryngology-head & neck surgery residency at the Medical College of Wisconsin. He completed a fellowship in rhinology and allergy at Oregon Health Sciences University. Dr Han is board certified in otolaryngology - head & neck surgery.

Dr Han is very active in both basic science research and clinical research studies. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigator for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis, and nasal polyposis.

Dr Han has served in many societies, including serving as the president for the Virginia Society of Otolaryngology, the Tidewater Otolaryngology & Ophthalmology Society, and the Korean American Otolaryngology Society, and as Chair of the Rhinology and Paranasal Sinus Committee within the American Academy of Otolaryngology & Head and Neck Surgery. Dr Han is currently the President Elect for the American Rhinologic Society and will be the President in the fall of 2020. He is one of the few physicians who is a fellow of the ARS, AAAAI, and AAOA.

Dr Han is an Associate Editor and on the Editorial Board for the International Forum of Allergy and Rhinology and is currently a guest examiner for the American Board of Otolaryngology & Head and Neck Surgery. He has over 94 scientific publications, over 157 national and international scientific presentations, and over 148 guest lectureships.

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Anju T. Peters, MD, MS, is a professor in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Peters graduated from the University of Michigan Medical School and completed her residency and fellowship in the division of allergy-immunology at Northwestern University Feinberg School of Medicine. She currently serves as the director of clinical research in the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine. She practices as an allergist in the Division of Allergy-Immunology and in the Sinus and Allergy Center of Northwestern University. Dr Peters is board certified in allergy and immunology.

Dr Peters has specific interest in taking care of patients with chronic rhinosinusitis, with and without nasal polyps, and associated conditions of asthma and immunodeficiencies. She has focused her research in the field of chronic rhinosinusitis and its associated comorbidities, including allergic rhinitis, asthma, and immunodeficiencies.

Dr Peters has published extensively in these areas and is currently involved in clinical trials in asthma and chronic rhinosinusitis. She is the current chair of the AAAAI/ACAAI Joint Task Force practice parameters on chronic rhinosinusitis, which are leading guidelines on the treatment of chronic rhinosinusitis. In addition to her work on the national practice guidelines in the field of rhinosinusitis, Dr Peters has been invited to present original clinical research and lectures at local, national, and international meetings.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YoubeeCare (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Speaker’s Bureau: Galderma, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche Posay/L’Oreal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, YobeeCare (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on November 23, 2020 and is valid for one year. Requests for credit must be made no later than November 23, 2021.

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity
  • Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

0.25 CME
Vindico
Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management

Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to select treatment for patients with psoriasis based on the latest clinical evidence and recommendations.

Activity Description

In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Departments of Dermatology and Pathology
Co-Medical Director of Continuing Medical Education
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Actellion, Mallinkrodt, Novartis, UCB
Speakers Bureau: AbbVie, Mallinkrodt, Novartis
Contracted Research: Mallinkrodt, Novartis
Research Support for Clinical Trials: Corbus, Pfizer


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Pages